Patents by Inventor Russell Rother
Russell Rother has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Publication number: 20200055942Abstract: The present invention relates to the treatment or prevention of P-selectin mediated disorders, and to anti-P-selectin antibodies or binding fragments thereof, for use in the treatment or prevention of such disorders. In particular, the invention relates to the treatment or prevention of pain crises associated with sickle cell disease, and to anti-P-selectin antibodies or binding fragments thereof, for use in the treatment or prevention of pain crises associated with sickle cell disease.Type: ApplicationFiled: November 3, 2017Publication date: February 20, 2020Inventors: Scott ROLLINS, Russell ROTHER, Jonathan STOCKER, Andreas BRUEDERLE
-
Publication number: 20160304612Abstract: Antibodies are disclosed which bind specifically to P-selectin and which block the binding of PSGL-1 to P-selectin. These anti-P-selectin antibodies may also cause dissociation of preformed P-selectin/PSGL-1 complexes. The disclosure identifies a heretofore unrecognized, near N-terminal, antibody binding domain (a conformational epitope) of P-selectin to which the function-blocking antibodies (which may be chimeric, human or humanized antibodies for example) bind. Antibodies are disclosed which bind to the conformational epitope of P-selectin and which have a dual function in blocking binding of PSGL-1 to P-selectin, and in causing dissociation of preformed P-selectin/PSGL-1 complexes. Such single and dual function anti-P-selectin antibodies and binding fragments thereof may be used in the treatment of a variety of inflammatory and thrombotic disorders and conditions. Screening methods for identifying such antibodies are also disclosed.Type: ApplicationFiled: June 29, 2015Publication date: October 20, 2016Inventors: Richard Alvarez, Russell Rother, Rodger P. McEver, Ziad S. Kawar
-
Patent number: 9068001Abstract: Antibodies are disclosed which bind specifically to P-selectin and which block the binding of PSGL-1 to P-selectin. These anti-P-selectin antibodies may also cause dissociation of preformed P-selectin/PSGL-1 complexes. The disclosure identifies a heretofore unrecognized, near N-terminal, antibody binding domain (a conformational epitope) of P-selectin to which the function-blocking antibodies (which may be chimeric, human or humanized antibodies for example) bind. Antibodies are disclosed which bind to the conformational epitope of P-selectin and which have a dual function in blocking binding of PSGL-1 to P-selectin, and in causing dissociation of preformed P-selectin/PSGL-1 complexes. Such single and dual function anti-P-selectin antibodies and binding fragments thereof may be used in the treatment of a variety of inflammatory and thrombotic disorders and conditions. Screening methods for identifying such antibodies are also disclosed.Type: GrantFiled: August 5, 2011Date of Patent: June 30, 2015Assignees: Selexys Pharmaceuticals, Oklahoma Medical Research FoundationInventors: Scott Rollins, Richard Alvarez, Russell Rother, Rodger P. McEver, Ziad S. Kawar
-
Patent number: 8945565Abstract: Antibodies are disclosed which bind specifically to P-selectin and which block the binding of PSGL-1 to P-selectin. These anti-P-selectin antibodies may also cause dissociation of preformed P-selectin/PSGL-1 complexes. The disclosure identifies a heretofore unrecognized, near N-terminal, antibody binding domain (a conformational epitope) of P-selectin to which the function-blocking antibodies (which may be chimeric, human or humanized antibodies for example) bind. Antibodies are disclosed which bind to the conformational epitope of P-selectin and which have a dual function in blocking binding of PSGL-1 to P-selectin, and in causing dissociation of preformed P-selectin/PSGL-1 complexes. Such single and dual function anti-P-selectin antibodies and binding fragments thereof may be used in the treatment of a variety of inflammatory and thrombotic disorders and conditions. Screening methods for identifying such antibodies are also disclosed.Type: GrantFiled: December 21, 2010Date of Patent: February 3, 2015Assignees: Selexys Pharmaceuticals Corporation, Oklahoma Medical Research FoundationInventors: Scott Rollins, Richard Alvarez, Russell Rother, Rodger P. McEver, Ziad S. Kawar
-
Publication number: 20110293617Abstract: Antibodies are disclosed which bind specifically to P-selectin and which block the binding of PSGL-1 to P-selectin. These anti-P-selectin antibodies may also cause dissociation of preformed P-selectin/PSGL-1 complexes. The disclosure identifies a heretofore unrecognized, near N-terminal, antibody binding domain (a conformational epitope) of P-selectin to which the function-blocking antibodies (which may be chimeric, human or humanized antibodies for example) bind. Antibodies are disclosed which bind to the conformational epitope of P-selectin and which have a dual function in blocking binding of PSGL-1 to P-selectin, and in causing dissociation of preformed P-selectin/PSGL-1 complexes. Such single and dual function anti-P-selectin antibodies and binding fragments thereof may be used in the treatment of a variety of inflammatory and thrombotic disorders and conditions. Screening methods for identifying such antibodies are also disclosed.Type: ApplicationFiled: December 21, 2010Publication date: December 1, 2011Inventors: Scott Rollins, Richard Alvarez, Russell Rother, Rodger P. McEver, Ziad S. Kawar
-
Publication number: 20110287017Abstract: Antibodies are disclosed which bind specifically to P-selectin and which block the binding of PSGL-1 to P-selectin. These anti-P-selectin antibodies may also cause dissociation of preformed P-selectin/PSGL-1 complexes. The disclosure identifies a heretofore unrecognized, near N-terminal, antibody binding domain (a conformational epitope) of P-selectin to which the function-blocking antibodies (which may be chimeric, human or humanized antibodies for example) bind. Antibodies are disclosed which bind to the conformational epitope of P-selectin and which have a dual function in blocking binding of PSGL-1 to P-selectin, and in causing dissociation of preformed P-selectin/PSGL-1 complexes. Such single and dual function anti-P-selectin antibodies and binding fragments thereof may be used in the treatment of a variety of inflammatory and thrombotic disorders and conditions. Screening methods for identifying such antibodies are also disclosed.Type: ApplicationFiled: August 5, 2011Publication date: November 24, 2011Inventors: Scott Rollins, Richard Alvarez, Russell Rother, Rodger P. McEver, Ziad S. Kawar
-
Publication number: 20110230646Abstract: Hybrid antibodies and/or hybrid antibody fragments and methods of making them are provided. In one embodiment the hybrid antibodies and/or hybrid antibody fragments 5 contain heavy and/or light variable regions that contain two or more framework regions derived from at least two antibodies. In another embodiment, at least two of the framework regions are classified in the same germline gene family. In one embodiment, at least two framework regions are classified in the same germline gene family member. The hybrid antibodies or hybrid antibody fragments may contain human framework regions and 10 nonhuman CDRs.Type: ApplicationFiled: April 18, 2011Publication date: September 22, 2011Applicant: Alexion Pharmaceuticals, Inc.Inventors: Russell Rother, Dayang Wu
-
Publication number: 20110212096Abstract: Antibodies are disclosed which bind specifically to P-selectin and which block the binding of PSGL-1 to P-selectin. These anti-P-selectin antibodies may also cause dissociation of preformed P-selectin/PSGL-1 complexes. The disclosure identifies a heretofore unrecognized, near N-terminal, antibody binding domain (a conformational epitope) of P-selectin to which the function-blocking antibodies (which may be chimeric, human or humanized antibodies for example) bind. Antibodies are disclosed which bind to the conformational epitope of P-selectin and which have a dual function in blocking binding of PSGL-1 to P-selectin, and in causing dissociation of preformed P-selectin/PSGL-1 complexes. Such single and dual function anti-P-selectin antibodies and binding fragments thereof may be used in the treatment of a variety of inflammatory and thrombotic disorders and conditions. Screening methods for identifying such antibodies are also disclosed.Type: ApplicationFiled: December 21, 2010Publication date: September 1, 2011Inventors: Scott Rollins, Richard Alvarez, Russell Rother, Rodger P. McEver, Ziad S. Kawar
-
Publication number: 20110021758Abstract: Hybrid antibodies and/or hybrid antibody fragments and methods of making them are provided. In one embodiment the hybrid antibodies and/or hybrid antibody fragments contain heavy and/or light variable regions that contain two or more framework regions derived from at least two antibodies. In another embodiment, at least two of the framework regions are classified in the same germline gene family. In one embodiment, at least two framework regions are classified in the same germline gene family member. The hybrid antibodies or hybrid antibody fragments may contain human framework regions and nonhuman CDRs.Type: ApplicationFiled: September 17, 2010Publication date: January 27, 2011Applicant: Alexion Pharmaceuticals, Inc.Inventors: Russell Rother, Dayang Wu
-
Publication number: 20100076177Abstract: Hybrid antibodies and/or hybrid antibody fragments and methods of making them are provided. In one embodiment the hybrid antibodies and/or hybrid antibody fragments contain heavy and/or light variable regions that contain two or more framework regions derived from at least two antibodies. In another embodiment, at least two of the framework regions are classified in the same germline gene family. In one embodiment, at least two framework regions are classified in the same germline gene family member. The hybrid antibodies or hybrid antibody fragments may contain human framework regions and nonhuman CDRs.Type: ApplicationFiled: June 30, 2008Publication date: March 25, 2010Applicant: Alexion Pharmaceuticals, Inc.Inventors: Russell Rother, Dayang Wu
-
Patent number: 7393648Abstract: Hybrid antibodies and/or hybrid antibody fragments and methods of making them are provided. In one embodiment the hybrid antibodies and/or hybrid antibody fragments contain heavy and/or light variable regions that contain two or more framework regions derived from at least two antibodies. In another embodiment, at least two of the framework regions are classified in the same germline gene family. In one embodiment, at least two framework regions are classified in the same germline gene family member. The hybrid antibodies or hybrid antibody fragments may contain human framework regions and nonhuman CDRs.Type: GrantFiled: June 3, 2003Date of Patent: July 1, 2008Assignee: Alexion Pharmaceuticals, Inc.Inventors: Russell Rother, Dayang Wu
-
Publication number: 20070292416Abstract: Antibodies or functional antibody fragments that recognize or interfere with the production of a component of the CD3 antigen complex are de-immunized.Type: ApplicationFiled: May 28, 2004Publication date: December 20, 2007Applicant: Alexion Pharmaceuticals, Inc.Inventors: Russell Rother, Susan McKnight, Dayang Wu, Francis Carr, Anita Hamilton
-
Publication number: 20070116710Abstract: Paroxysmal nocturnal hemoglobinuria or other hemolytic diseases are treated using a compound which binds to or otherwise blocks the generation and/or the activity of one or more complement components, such as, for example, a complement-inhibiting antibody.Type: ApplicationFiled: November 8, 2006Publication date: May 24, 2007Inventors: Leonard Bell, Russell Rother
-
Publication number: 20070041972Abstract: Antibodies and/or fusion proteins contain a region that includes an IgG2-derived portion IgG4-derived portion.Type: ApplicationFiled: May 28, 2004Publication date: February 22, 2007Applicant: ALEXION PHARMACEUTICALS, INC.Inventors: Russell Rother, Dayang Wu, Stephen Squinto, Mark Evans, Susan McKnight
-
Publication number: 20050221382Abstract: The present disclosure is directed to screening, diagnosing and treating patients having, or suspected of having, rheumatoid arthritis. Levels of glucose-6-phophate isomerase or antibodies to glucose-6-phophate isomerase are assayed in test subjects or populations to determine susceptibility to, or existence of, an antibody mediated form of rheumatoid arthritis in such test subjects or populations. The results of the assays provide guidelines for therapeutic intervention with complement inhibiting agents.Type: ApplicationFiled: March 17, 2003Publication date: October 6, 2005Inventor: Russell Rother
-
Publication number: 20050191298Abstract: Paroxysmal nocturnal hemoglobinuria or other hemolytic diseases are treated using a compound which binds to or otherwise blocks the generation and/or the activity of one or more complement components, such as, for example, a complement-inhibiting antibody.Type: ApplicationFiled: February 3, 2005Publication date: September 1, 2005Inventors: Leonard Bell, Russell Rother
-
Publication number: 20050169921Abstract: Paroxysmal nocturnal hemoglobinuria or other hemolytic diseases are treated using a compound which binds to or otherwise blocks the generation and/or the activity of one or more complement components, such as, for example, a complement-inhibiting antibody.Type: ApplicationFiled: February 3, 2004Publication date: August 4, 2005Inventors: Leonard Bell, Russell Rother
-
Publication number: 20040038308Abstract: Hybrid antibodies and/or hybrid antibody fragments and methods of making them are provided. In one embodiment the hybrid antibodies and/or hybrid antibody fragments contain heavy and/or light variable regions that contain two or more framework regions derived from at least two antibodies. In another embodiment, at least two of the framework regions are classified in the same germline gene family. In one embodiment, at least two framework regions are classified in the same germline gene family member. The hybrid antibodies or hybrid antibody fragments may contain human framework regions and nonhuman CDRs.Type: ApplicationFiled: June 3, 2003Publication date: February 26, 2004Inventors: Russell Rother, Dayang Wu
-
Patent number: 5847082Abstract: Nucleic acid sequences encoding chimeric proteins that comprise a functional portion of a parent terminal complement inhibitor, such as CD59, and a heterologous transmembrane domain are provided. The parent terminal complement inhibitor is modified to inactivate its GPI signal sequence. The heterologous transmembrane domain serves to anchor the chimeric protein to the cell membrane without substantially interfering with the complement inhibitor activity of the terminal complement inhibitor. The nucleic acid sequences and encoded chimeric proteins can be used to protect cells from complement attack.Type: GrantFiled: June 7, 1995Date of Patent: December 8, 1998Assignee: Alexion Pharmaceuticals, Inc.Inventors: Russell Rother, Scott Rollins, Stephen P. Squinto